These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29540729)

  • 1. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer.
    Sheng N; Yan L; Wu K; You W; Gong J; Hu L; Tan G; Chen H; Wang Z
    Cell Death Dis; 2018 Mar; 9(3):402. PubMed ID: 29540729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRIP13 promotes metastasis of colorectal cancer regardless of p53 and microsatellite instability status.
    Agarwal S; Behring M; Kim HG; Chandrashekar DS; Chakravarthi BVSK; Gupta N; Bajpai P; Elkholy A; Al Diffalha S; Datta PK; Heslin MJ; Varambally S; Manne U
    Mol Oncol; 2020 Dec; 14(12):3007-3029. PubMed ID: 33037736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DCZ0415, a small-molecule inhibitor targeting TRIP13, inhibits EMT and metastasis via inactivation of the FGFR4/STAT3 axis and the Wnt/β-catenin pathway in colorectal cancer.
    Agarwal S; Afaq F; Bajpai P; Kim HG; Elkholy A; Behring M; Chandrashekar DS; Diffalha SA; Khushman M; Sugandha SP; Varambally S; Manne U
    Mol Oncol; 2022 Apr; 16(8):1728-1745. PubMed ID: 35194944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIP13 Activates Glycolysis to Promote Cell Stemness and Strengthen Doxorubicin Resistance of Colorectal Cancer Cells.
    Liu G; Wang H; Ran R; Wang Y; Li Y
    Curr Med Chem; 2024; 31(22):3397-3411. PubMed ID: 38347785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel norcantharidin derivative DCZ5417 suppresses multiple myeloma progression by targeting the TRIP13-MAPK-YWHAE signaling pathway.
    Wang Y; Dong S; Hu K; Xu L; Feng Q; Li B; Wang G; Chen G; Zhang B; Jia X; Xu Z; Gao X; Zhang H; Xie Y; Lu M; Chang S; Song D; Wu X; Jia Q; Zhu H; Zhou J; Zhu W; Shi J
    J Transl Med; 2023 Nov; 21(1):858. PubMed ID: 38012658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TRIP13 for overcoming anticancer drug resistance (Review).
    Zhao L; Ye S; Jing S; Gao YJ; He T
    Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CYP24A1, AHR, CPEB4, TRIP13, and PIK3CA genes expression in colorectal cancer patients: novel diagnostic biomarkers.
    El Nakib AM; Elsaeed M; Abdelsalam RA; Wafi K; Elekhnawy E; Alrouji M; Alsaleem M; Aljarba NH; Batiha GE; Negm WA; Mostafa SA
    Eur Rev Med Pharmacol Sci; 2023 Sep; 27(17):7946-7955. PubMed ID: 37750623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TI17, a novel compound, exerts anti-MM activity by impairing Trip13 function of DSBs repair and enhancing DNA damage.
    Chang S; Xiao W; Xie Y; Xu Z; Li B; Wang G; Hu K; Zhang Y; Zhou J; Song D; Zhu H; Wu X; Lu Y; Shi J; Zhu W
    Cancer Med; 2023 Dec; 12(23):21321-21334. PubMed ID: 37942576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 14-3-3 Proteins: diverse functions in cell proliferation and cancer progression.
    Freeman AK; Morrison DK
    Semin Cell Dev Biol; 2011 Sep; 22(7):681-7. PubMed ID: 21884813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivo.
    Dong S; Hu K; Shi Y; Wang G; Yu D; Zhao Y; Zhang H; Wang Y; Sun H; Xu Z; Jia Q; Li Y; Li Y; Li B; Shi J; Zhu W
    Bioorg Med Chem Lett; 2024 Jan; 98():129590. PubMed ID: 38092072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIP13 - a potential drug target in cancer pharmacotherapy.
    Jacob Bunu S; Cai H; Wu L; Zhang H; Zhou Z; Xu Z; Shi J; Zhu W
    Bioorg Chem; 2024 Jul; 151():107650. PubMed ID: 39042962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant activation of TRIP13-EZH2 signaling axis promotes stemness and therapy resistance in multiple myeloma.
    Xu L; Wang Y; Wang G; Guo S; Yu D; Feng Q; Hu K; Chen G; Li B; Xu Z; Jia X; Lu Y; Zhang H; Gao X; Chang S; Wang H; Wu X; Song D; Yang G; Zhu H; Zhou J; Zhan F; Zhu W; Shi J
    Leukemia; 2023 Jul; 37(7):1576-1579. PubMed ID: 37157015
    [No Abstract]   [Full Text] [Related]  

  • 13. An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.
    Dhasmana S; Dhasmana A; Rios S; Enriquez-Perez IA; Khan S; Afaq F; Haque S; Manne U; Yallapu MM; Chauhan SC
    Comput Struct Biotechnol J; 2023; 21():5765-5775. PubMed ID: 38074464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma.
    Li W; Zhang G; Li X; Wang X; Li Q; Hong L; Shen Y; Zhao C; Gong X; Chen Y; Zhou J
    Biochem Biophys Res Commun; 2018 May; 499(3):416-424. PubMed ID: 29567476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
    Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
    Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4.
    Zhu MX; Wei CY; Zhang PF; Gao DM; Chen J; Zhao Y; Dong SS; Liu BB
    J Exp Clin Cancer Res; 2019 Sep; 38(1):409. PubMed ID: 31533816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of thyroid hormone receptor interactor 13 is associated with human hepatocellular carcinoma.
    Ju L; Li X; Shao J; Lu R; Wang Y; Bian Z
    Oncol Rep; 2018 Dec; 40(6):3794-3802. PubMed ID: 30542731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TRIP13 interference inhibits the proliferation and metastasis of thyroid cancer cells through regulating TTC5/p53 pathway and epithelial-mesenchymal transition related genes expression.
    Yu L; Xiao Y; Zhou X; Wang J; Chen S; Peng T; Zhu X
    Biomed Pharmacother; 2019 Dec; 120():109508. PubMed ID: 31648166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway.
    Gao Y; Liu S; Guo Q; Zhang S; Zhao Y; Wang H; Li T; Gong Y; Wang Y; Zhang T; Dong Z; Bacich D; Chowdhury WH; Rodriguez R; Wang Z
    Int J Biol Sci; 2019; 15(7):1488-1499. PubMed ID: 31337978
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.